Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Aim: This study demonstrated potent inhibitors against COVID-19 using the molecular docking approach of FDA approved viral antiprotease drugs.
Background: COVID-19 has now spread throughout world. There is a serious need to find potential therapeutic agents. The 3C-like protease (Mpro/6LU7) is an attractive molecular target for rational anti-CoV drugs
Methods: The tertiary structure of COVID-19 Mpro was obtained from a protein data bank repository, and molecular docking screening was performed by Molegro Virtual Docker, ver. 6, with a grid resolution of 0.30 Å. Docking scores (DOS) are representative of calculated ligand-receptor (protein) interaction energy; therefore, more negative scores mean better binding tendency. Another docking study was then applied on each of the selected drugs with the best ligands separately and using a more accurate RMSD algorithm.
Results The docking of COVID-19 major protease (6LU7) with 17 selected drugs resulted in four FDA approved viral antiprotease drugs (Temoporfin, Simeprevir, Cobicistat, Ritonavir) showing the best docking scores. Among these 4 compounds, Temoporfin exhibited the best DOS (-202.88) and the best screened ligand with COVID-19 Mpro, followed by Simeprevir (-201.66), Cobicistat (-187.75), and Ritonavir (-186.66). As the best screened ligand, Temoporfin could target the Mpro with 20 different conformations, while Simeprevir, Cobicistat, and Ritonavir make 14, 10, and 10 potential conformations at the binding site, respectively.
Conclusion: The findings showed that the four selected FDA approved drugs can be potent inhibitors against COVID-19; among them, Temoporfin may be more potent for the treatment of the disease. Based on the findings, it is recommended that in-vitro and in-vivo evaluations be conducted to determine the effectiveness of these drugs against COVID-19.
Keywords: COVID-19, Main protease, Mpro/6LU7, Molecular docking, Viral antiprotease drugs.
(Please cite as: Absalan AR, Doroud D, Salehi-Vaziri M, Kaghazian H, Ahmadi N, Zali F, et al. Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19. Gastroenterol Hepatol Bed Bench 2020;13(4):355-360).
- COVID-19, Main protease, Mpro/6LU7, Molecular docking, Viral antiprotease drugs.
Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis 2020;71:882-3.
He F, Deng Y, Li W. Coronavirus Disease 2019 (COVID‐19): What we know? J med virol 2020;92:719-25.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497-506.
Mardani R, Vasmehjani AA, Zali F, Gholami A, Nasab SDM, Kaghazian H, et al. Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study. Arch Acad Emerg Med 2020;8:e43.
Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, et al. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Quart 2020;40:68-76.
Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020:102434.
To KK, Hung IF, Chan JF, Yuen KY. From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis 2013;5:S103-8.
Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 2013;19:736.
Frick D, Virdi RS, Vuksanovic N, Dahal N, Silvaggi NR. Variable Macro X Domain of SARS-CoV-2 Retains the Ability to Bind ADP-ribose. bioRxiv 2020.
Andrade B, Ghosh P, Barth D, Tiwari S, Silva RJS, de Assis Soares WR, et al. Computational screening for potential drug candidates against SARS-CoV-2 main protease. Preprints 2020; 2020040003.
Krichel B, Falke S, Hilgenfeld R, Redecke L, Uetrecht C. Processing of the SARS-CoV pp1a/ab nsp7-10 region. Biochem J 2020;477:1009-19.
Fahmi M, Kubota Y, Ito M. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV. Infect Genet Evol 2020;81:104272.
Keyvani H, Ahmadi NA, Ranjbar MM, Ataei-Kachooei S, Ghorban K, Dadmanesh M. mmunoinformatics Study of gp120 of Human Immunodeficiency Virus Type 1 Subtype CRF35_AD Isolated from Iranian Patients. Arch Clin Infect Dis 2016;11:e36270.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 2020;582:289-93.
Senge MO, Brandt JC. Temoporfin (Foscan®, 5, 10, 15, 20‐tetra (m‐hydroxyphenyl) chlorin)—a second‐generation photosensitizer. Photochem Photobiol 2011;87:1240-96.
Lorenz K, Maier H. Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan. HNO 2008;56:402-9.
Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell res 2017;27:1046-64.
Sousa FS, Cerqueira N MFSA, A Fernandes P, Joao-Ramos M. Virtual screening in drug design and development. Comb Chem High Throughput Screen 2010;13:442-53.
Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012;52:1757-68.
Liu X, Zhang B, Jin Z, Yang H, Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor N3. 2020, DOI: 10.2210/pdb6LU7/pdb.
Lin C. HCV NS3-4A Serine Protease. In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience 2006.
Lin MV, Chung R. Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clin Liver Dis 2014;3:65-8.
Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020;38:379-81.
Dorward J, Gbinigie K. Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19. 2020. https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/.
Baz M, Boivin G. Antiviral agents in development for Zika virus infections. Pharmaceuticals 2019;12:101.
Wiehe A, O'Brien JM, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci 2019;18:2565-612.
Mottin M, Borba JV, Braga RC, Torres PH, Martini MC, Proenca-Modena JL, et al. The A–Z of Zika drug discovery. Drug Discov Today 2018;23:1833-47.
Wang L, Liang R, Gao Y, Li Y, Deng X, Xiang R, et al. Development of small-molecule inhibitors against zika virus infection. Front Microbiol 2019;10:2725.
Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design. Int J Mol Sci 2020;21:3099.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times